ctDNA and Metabolites in CSF as Early Biomarkers of Secondary CNS Involvement in Diffuse Large B-cell Lymphoma

  • End date
    Jun 1, 2023
  • participants needed
  • sponsor
    Herlev Hospital
Updated on 18 February 2021


The study is a prospective clinical study which investigates the use of new diagnostic methods to localize aggressive lymphoma involving the central nervous system(CNS). By measuring cell-free tumor DNA and metabolomics in cerebrospinal fluid and blood in patients with systemic Diffuse Large B-cell Lymphoma the investigators aim to improve the diagnostic certainty of an impending relapse of lymphoma in CNS.


Diffuse Large B-cell Lymphoma is a malignant, aggressive cancer representing 40% of Non-Hodgkin Lymphomas globally. The risk of relapse after primary treatment is approximately 30% of which up to 10 % occurs in the central nervous system (CNS). The prognosis after CNS relapse is severely discouraging with an overall survival of 3-6 months. Currently CNS relapse is diagnosed by either flow cytometry performed on cerebrospinal fluid or a stereotactic biopsy based on tumor localization by an MRI scan. Both diagnostic methods however require a certain tumor mass in order avoid false negative test results.

The purpose of this study is to learn whether tumor-derived cell-free circulating DNA (cfDNA) and/or metabolite profiles from diffuse large B-cell lymphoma (DLBCL) cells can be identified in the cerebrospinal fluid (CSF), before the malignant cells themselves are detectable in CSF. Thus the investigators aim to investigate the diagnostic potential of cfDNA and/or metabolites measured in blood and cerebrospinal fluid. The study is based on the following four hypotheses:

Hypothesis 1: Measurement of cfDNA and/or metabolites in CSF are more sensitive methods of detecting DLBCL involvement in CNS compared to conventional diagnostics.

Hypothesis 2: Quantitative cfDNA/metabolomics in CSF has independent prognostic value in DLBCL.

Hypothesis 3: cfDNA and/or metabolite profile in CSF detected at primary diagnosis predicts relapse of DLBCL in the CNS also when CNS-IPI is taken into account.

Hypothesis 4: Particular aberrations of cfDNA and/or metabolite profiles detected in blood (plasma) may, in some cases, be associated with CNS involvement in DLBCL patients and/or predict CNS relapse.

The study is composed of a pilot study including 5 patients with verified either primary or secondary CNS lymphoma followed by two studies: One including 40 patients with de novo DLBCL and one including 30 patients in a relapse setting. The patients will have to consent to having a lumbar puncture performed and blood samples taken before treatment initiation. After treatment a second set of lumbar puncture and blood samples will be requested.

Condition Diffuse Large B-Cell Lymphoma, CNS Metastases, diffuse large cell lymphoma, diffuse large b cell lymphoma, cns involvement
Clinical Study IdentifierNCT04112238
SponsorHerlev Hospital
Last Modified on18 February 2021


Yes No Not Sure

Inclusion Criteria

Is your age greater than or equal to 18 yrs?
Gender: Male or Female
Do you have any of these conditions: cns involvement or CNS Metastases or diffuse large b cell lymphoma or diffuse large cell lymphoma or Diffuse Large B-Cell Lymphoma?
Do you have any of these conditions: diffuse large cell lymphoma or CNS Metastases or Diffuse Large B-Cell Lymphoma or cns involvement or diffuse large b cell lymphoma?
Do you have any of these conditions: diffuse large cell lymphoma or CNS Metastases or Diffuse Large B-Cell Lymphoma or cns involvement or diffuse large b cell lymphoma?
A newly diagnosed and histologically verified DLBCL
No prior DLBCL treatments
Anti-lymphoma treatment not initiated (except pretreatment with corticosteroids)
CNS-IPI >/= 3
Being able to undergo standard assessment ( eg, Fluorine-18 fluorodeoxyglucose positron emission tomography (18F-FDG-PET), MRI of the neuroaxis and bone marrow biopsy)
Tumor biopsy and/or bone-marrow biopsy used for diagnosis available
Age 18 years
ECOG performance status of 0, 1 or 2
Life expectancy >/= 12 weeks
Patient must consent to permit genetic analysis of their cancer
Patient must consent to permit access to records in order to ascertain progression or relapse of their cancer
Written informed consent

Exclusion Criteria

Evidence of a CNS mass creating mass-effect or midline shift such that lumbar puncture is contraindicated
Other contraindications to lumbar puncture according to local guidelines
Other previous or current hematological malignancy
Previous or current primary CNS malignancy including primary CNS lymphoma
Prior treatment for CNS disease
Known CNS autoimmune or inflammatory disease
Known HIV infection
Patient is currently receiving treatment for DLBCL (except pretreatment with corticosteroids)
Clear my responses

How to participate?

Step 1 Connect with a site
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact


Phone Email

Please verify that you are not a bot.

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider


Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note